Trials / Completed
CompletedNCT01259557
Efficacy and Safety Study of Meditoxin® to Treat Essential Blepharospasm
Multi-center, Phase Ⅳ, Single Arm, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Meditoxin® in Subjects With Essential Blepharospasm
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 110 (actual)
- Sponsor
- Medy-Tox · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of Meditoxin® in the treatment of Essential blepharospasm.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Botulinum Toxin Type A | 2 times, Intra-muscular injection, Maximum dosage total 60U |
Timeline
- Start date
- 2010-08-01
- Primary completion
- 2011-05-01
- Completion
- 2011-08-01
- First posted
- 2010-12-14
- Last updated
- 2012-04-25
Locations
3 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01259557. Inclusion in this directory is not an endorsement.